VB-201 What it Does: VB-201 is a Lecinoxoid intended to reduce the effects of Atherosclerosis and other indications by harnessing the ability of oxidized phospholipids to inhibit immune-inflammatory responses.
Key Differentiator(s): Mimics the response of natural molecules but synthetically manipulated to increase stability and to target specific receptors.
Has dual mechanisms to increase probability of reducing inflammation; it inhibits points of cellular toll-like receptor signaling, and inhibits the migration of monocytes. Phase / Status / Expected Launch: Completed Phase 2 study for vascular inflammation. Currently planning Phase 3 trial for Atherosclerosis.
Expected Market: According to the National Institute of Health, approximately 50 million Americans suffer from some sort of autoimmune diseases.Other Considerations: In active pre-clinical investigation stage for other indications.
Vascular Biogenics has indicated that other small molecules being developed may offer higher potency or selectivity compared to this candidate.